GCM
ZBH icon

Glenview Capital Management’s Zimmer Biomet ZBH Stock Holding History

Glenview Capital Management’s Portfolio ZBH Stock Details ZBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-3,250,048
Closed -$369M – 62
2017
Q3 		$369M Buy
3,250,048
+2,455,496
+309% +$283M 2.14% 19
2017
Q2 		$99M Hold
794,552
– – 0.64% 41
2017
Q1 		$94.2M Buy
+794,552
New +$90.1M 0.62% 38

Other funds holding ZBH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
LP
Longview Partners St Peter Port, Guernsey $7.06B AUM 3.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Glenview Capital Management's ZBH Position: Q4 2017 in Review

Glenview Capital Management sold out of Zimmer Biomet (ZBH) in Q4 2017, closing a stake of 3,250,048 shares — an estimated $369M sold.

Glenview Capital Management first reported a position in ZBH in Q1 2017 and held it in 3 quarters. The position peaked at $369M in Q3 2017. 870 funds tracked by Wall St. Rank hold ZBH as of Q4 2017.

  • Glenview Capital Management reported no remaining Zimmer Biomet position as of Q4 2017 after selling out during the quarter.
  • Glenview Capital Management sold 3,250,048 Zimmer Biomet shares in Q4 2017, an estimated $369M.
  • Glenview Capital Management first reported a position in Zimmer Biomet in Q1 2017 and held it in 3 quarters.
  • Glenview Capital Management's Zimmer Biomet position peaked at $369M in Q3 2017.
  • 870 funds tracked by Wall St. Rank held Zimmer Biomet as of Q4 2017.

Based on Glenview Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.